Breast cancer research continues to transform lives through groundbreaking discoveries and innovative treatments that offer real hope to millions of patients worldwide. This comprehensive update is designed for patients, caregivers, healthcare professionals, and anyone interested in the latest scientific advances that are changing how we fight this disease.
Recent developments span from revolutionary treatment breakthroughs that are dramatically improving patient outcomes to cutting-edge diagnostic technologies that catch cancer earlier than ever before. Major pharmaceutical companies and research institutions, including the Department of Defense breast cancer research program, are pushing the boundaries of what’s possible through targeted therapies and personalized medicine approaches.
We’ll explore the most promising clinical trials currently delivering hope for future treatments, including immunotherapy advances and precision medicine approaches that target specific cancer subtypes. You’ll also discover how global research initiatives are accelerating medical progress, from the Uganda breast cancer research group’s work in underserved populations to World breast cancer research day initiatives that unite researchers across continents. Finally, we’ll cover the latest prevention and lifestyle research that’s empowering people to take proactive steps in managing their health risks.
Revolutionary Treatment Breakthroughs Transforming Patient Outcomes
Targeted Therapy Advances Offering Personalized Treatment Options
Precision medicine has completely changed how doctors approach breast cancer treatment. Instead of the one-size-fits-all approach from decades past, oncologists now analyze each patient’s tumor at the molecular level to create customized treatment plans. HER2-targeted therapies like trastuzumab deruxtecan (T-DXd) are showing remarkable results, with response rates exceeding 60% in heavily pretreated patients who previously had limited options.
CDK4/6 inhibitors paired with hormone therapy have extended progression-free survival by more than two years for patients with hormone receptor-positive breast cancer. These oral medications allow patients to maintain their quality of life while fighting the disease. Recent studies from leading breast cancer research institutions show that ribociclib can reduce the risk of death by 32% when combined with fulvestrant.
PI3K inhibitors represent another breakthrough, particularly for patients with PIK3CA mutations. Alpelisib, combined with fulvestrant, targets this specific genetic alteration found in about 40% of hormone receptor-positive breast cancers. Clinical data demonstrates that patients with these mutations experience significantly longer progression-free survival compared to standard therapy alone.
Antibody-drug conjugates are revolutionizing treatment by acting like guided missiles that deliver chemotherapy directly to cancer cells while sparing healthy tissue. These smart drugs reduce side effects and improve effectiveness, giving patients better outcomes with less toxicity.
Immunotherapy Innovations Boosting Natural Cancer Fighting Abilities
Cancer’s ability to hide from the immune system has been one of its most formidable defenses, but new immunotherapy approaches are teaching the body how to fight back. Checkpoint inhibitors like pembrolizumab have shown impressive results in triple-negative breast cancer, with some patients achieving complete pathologic responses when combined with chemotherapy before surgery.
PD-1 and PD-L1 inhibitors work by removing the molecular brakes that cancer cells use to evade immune detection. In metastatic triple-negative breast cancer, pembrolizumab combined with chemotherapy improved overall survival by several months, marking a significant milestone for this aggressive subtype that historically had few treatment options.
Vaccine-based immunotherapies are entering clinical trials with promising early results. These treatments train the immune system to recognize and attack specific proteins found on breast cancer cells. Unlike traditional vaccines that prevent disease, therapeutic vaccines help the body mount a stronger immune response against existing cancer.
Adoptive cell therapy involves extracting a patient’s immune cells, enhancing them in the laboratory, then reinfusing them back into the patient. Tumor-infiltrating lymphocytes (TILs) therapy has shown remarkable responses in some patients with advanced disease, with response rates reaching 20-30% in heavily pretreated cases.
CAR-T Cell Therapy Developments Providing New Hope for Advanced Cases
CAR-T cell therapy represents one of the most exciting frontiers in breast cancer treatment. Scientists extract T-cells from patients and genetically modify them to better recognize and attack cancer cells. These supercharged immune cells are then multiplied in the lab and returned to the patient as a living drug.
Early-phase trials targeting HER2-positive breast cancer with CAR-T cells have shown encouraging results. Researchers at major cancer centers are reporting tumor shrinkage in patients who had exhausted all other treatment options. The challenge lies in making these therapies effective against solid tumors, which are more complex than blood cancers where CAR-T therapy first proved successful.
Next-generation CAR-T approaches include dual-targeting designs that recognize multiple proteins on cancer cells simultaneously. This strategy helps prevent cancer cells from escaping by losing one target protein. Armored CAR-T cells are engineered to produce additional immune-stimulating proteins that help overcome the suppressive tumor environment.
Recent developments include off-the-shelf CAR-T products that don’t require individualized manufacturing. These universal CAR-T cells could make this revolutionary treatment more accessible and affordable. Clinical trials are testing these approaches in various breast cancer subtypes, with some showing response rates of 15-20% in heavily pretreated patients.
Combination Treatment Strategies Maximizing Therapeutic Effectiveness
The most significant advances in breast cancer care are coming from smart combinations that attack the disease from multiple angles. Triple combination strategies incorporating targeted therapy, immunotherapy, and traditional treatments are showing unprecedented results in clinical trials.
CDK4/6 inhibitors combined with hormone therapy and PI3K inhibitors create a powerful blockade against hormone receptor-positive breast cancer. This triple approach targets different growth pathways simultaneously, making it harder for cancer cells to develop resistance. Studies show improved outcomes with manageable side effects when these drugs are carefully sequenced.
Immunotherapy combinations are particularly promising for triple-negative breast cancer. Pembrolizumab plus chemotherapy followed by surgery, then additional immunotherapy, has achieved pathologic complete response rates exceeding 60% in some trials. These combinations are transforming what was once considered an incurable diagnosis into a potentially curable disease.
Sequential therapy strategies optimize the timing of different treatments. Pre-surgical (neoadjuvant) combinations can shrink tumors before surgery, while post-surgical (adjuvant) approaches eliminate remaining cancer cells. This coordinated attack maximizes the chance of cure while minimizing unnecessary toxicity.
Top pharmaceutical companies breast cancer research efforts are increasingly focused on these rational combinations rather than single-agent approaches. The Department of Defense breast cancer research program and other major funding bodies are prioritizing studies that test innovative combination strategies, recognizing that the future of breast cancer treatment lies in smart, personalized combination approaches rather than one-drug solutions.
Promising Clinical Trials Delivering Hope for Future Treatments
Phase III Trial Results Showing Significant Survival Rate Improvements
Recent Phase III clinical trials have delivered groundbreaking results that are changing how doctors approach breast cancer treatment. The KEYNOTE-522 trial, which tested pembrolizumab combined with chemotherapy, showed a remarkable 37% reduction in disease recurrence or death compared to chemotherapy alone. This breakthrough has led to FDA approval for treating triple-negative breast cancer, one of the most aggressive forms of the disease.
Another game-changing study, the monarchE trial, demonstrated that adding abemaciclib to standard hormone therapy reduced the risk of cancer returning by 35% in patients with high-risk, hormone receptor-positive breast cancer. These results have already changed treatment guidelines worldwide, giving patients access to more effective options.
The DESTINY-Breast04 trial brought hope to patients with HER2-low breast cancer, a group that previously had limited targeted treatment options. The study showed that trastuzumab deruxtecan improved overall survival by 36% compared to standard chemotherapy. This success has opened doors for treating a much larger group of patients who can now benefit from precision medicine approaches.
Novel Drug Testing Programs Expanding Treatment Arsenal
Pharmaceutical companies are investing heavily in innovative drug testing programs that target previously untreatable breast cancer subtypes. CDK4/6 inhibitors represent one of the most successful drug classes to emerge in recent years, with multiple compounds now showing promise in various combinations and treatment settings.
Antibody-drug conjugates (ADCs) are revolutionizing targeted therapy approaches. Beyond trastuzumab deruxtecan, several new ADCs are showing impressive results in early-phase trials. Sacituzumab govitecan has already received approval for triple-negative breast cancer and is being tested in other subtypes with encouraging preliminary results.
The Department of Defense Breast Cancer Research Program continues funding innovative approaches, including novel immunotherapy combinations and cellular therapies. CAR-T cell therapy, traditionally used for blood cancers, is being adapted for solid tumors with promising early results in heavily pretreated patients.
Oral selective estrogen receptor degraders (SERDs) are showing potential to overcome resistance to current hormone therapies. These drugs work differently from existing treatments and may provide new options for patients whose cancer has stopped responding to standard hormone-blocking medications.
Biomarker Research Studies Enabling Earlier Detection Methods
Circulating tumor DNA (ctDNA) testing has emerged as a powerful tool for monitoring treatment response and detecting cancer recurrence months before conventional imaging. The CIRCULATE-Japan study demonstrated that ctDNA levels could predict treatment outcomes with remarkable accuracy, potentially allowing doctors to adjust therapy in real-time.
Liquid biopsy technologies are advancing rapidly, with multiple studies showing their ability to detect minimal residual disease after surgery. The c-TRAK TN study found that patients with detectable ctDNA after treatment had a significantly higher risk of recurrence, enabling more personalized follow-up care.
Multi-cancer early detection tests using methylation patterns and protein markers are showing promise for identifying breast cancer at its earliest stages. The PATHFINDER study demonstrated that these blood tests could detect cancer before symptoms appear, potentially catching the disease when it’s most treatable.
Artificial intelligence is being integrated into biomarker research, analyzing patterns in blood tests, imaging, and genetic data that human researchers might miss. Machine learning algorithms trained on thousands of patient samples are identifying new biomarker combinations that could improve both diagnosis and treatment selection.
The Uganda Breast Cancer Research Group and other international collaborations are studying biomarkers specific to different populations, recognizing that genetic variations across ethnic groups may require tailored approaches to early detection and treatment selection.
Cutting-Edge Diagnostic Technologies Revolutionizing Early Detection
AI-Powered Ai Imaging Systems Improving Accuracy and Speed
Artificial intelligence has completely changed how doctors spot breast cancer, making mammogram readings faster and way more accurate than ever before. These smart systems can analyze thousands of medical images in minutes, catching subtle signs that even experienced radiologists might miss.
Google’s AI system, for example, can reduce both false positives by 5.7% and false negatives by 9.4% compared to traditional methods. That means fewer women get called back for unnecessary follow-up tests, and fewer cancers slip through undetected. The technology works by training on millions of mammogram images, learning to recognize patterns that indicate cancer risk.
What makes these AI tools really powerful is their ability to work alongside doctors, not replace them. Radiologists using AI support make decisions 20% faster while maintaining higher accuracy rates. Some systems even highlight suspicious areas on the scan, acting like a second pair of expert eyes.
Several major medical centers now use AI screening tools as standard practice. The breast cancer research community has embraced these advances, with studies showing that AI-assisted screenings catch stage-one cancers 13% more often than traditional methods alone.
Liquid Biopsy Advancements Offering Non-Invasive Testing Solutions
Blood tests that detect cancer cells sound like science fiction, but they’re becoming reality in breast cancer diagnosis. Liquid biopsies analyze circulating tumor DNA (ctDNA) and cancer cells that break away from tumors and float through the bloodstream.
These tests offer huge advantages over traditional tissue biopsies. No needles, no surgical procedures, just a simple blood draw that patients can get at their regular doctor visits. The results can show not just whether cancer is present, but also what type and how it might respond to different treatments.
Recent breakthroughs have made these tests incredibly sensitive. Some can detect cancer DNA when there’s just one cancer cell among a million normal cells. Companies like Guardant Health and Foundation Medicine have developed tests that can track treatment progress and spot cancer recurrence months before traditional scans would catch it.
The breast cancer research and treatment field has seen remarkable progress here. Clinical trials show liquid biopsies can guide treatment decisions with 85% accuracy, helping doctors choose the most effective therapies without waiting for tumor tissue analysis.
Genetic Testing Breakthroughs Identifying High-Risk Individuals
Genetic testing has moved far beyond just checking for BRCA1 and BRCA2 mutations. Today’s tests examine dozens of genes linked to breast cancer risk, giving people a much clearer picture of their chances of developing the disease.
Multi-gene panel testing now screens for mutations in genes like PALB2, CHEK2, and ATM, which together account for significant portions of hereditary breast cancers. These comprehensive tests help identify women who might benefit from enhanced screening, preventive medications, or even preventive surgery.
The latest genetic risk scores combine multiple genetic variants to calculate personalized risk levels. These polygenic risk scores can identify women with twice the average risk of developing breast cancer, even when they don’t carry major mutations like BRCA.
Testing has become more accessible too. Direct-to-consumer genetic tests, while not as comprehensive as medical-grade testing, have introduced millions of people to their genetic risk factors. This awareness drives many to seek proper genetic counseling and medical evaluation.
Molecular Profiling Tools Guiding Precision Treatment Decisions
Molecular profiling examines the genetic makeup of individual tumors to predict how they’ll respond to specific treatments. This personalized approach has transformed breast cancer care, moving away from one-size-fits-all treatments.
Tests like Oncotype DX and MammaPrint analyze gene expression patterns in tumor tissue to predict recurrence risk and treatment response. These tests help doctors decide whether chemotherapy will actually benefit a patient or if hormone therapy alone might be enough.
Newer profiling technologies can identify rare genetic mutations that make tumors vulnerable to targeted drugs. For instance, tumors with HER2 mutations respond well to drugs like Herceptin, while those with BRCA mutations might benefit from PARP inhibitors.
Top pharmaceutical companies investing in breast cancer research rely heavily on these molecular insights to develop new targeted therapies. The approach has led to personalized treatment plans that improve outcomes while reducing unnecessary side effects from treatments that wouldn’t work anyway.
Real-time monitoring through molecular profiling also tracks how tumors change during treatment, allowing doctors to adjust strategies when resistance develops. This dynamic approach keeps treatments effective longer and gives patients better long-term outcomes.
Global Research Initiatives Accelerating Medical Progress
International Collaboration Programs Sharing Critical Research Data
Research institutions worldwide have created powerful networks that share breast cancer data across borders, breaking down traditional barriers that once slowed medical progress. The International Breast Cancer Study Group connects researchers from over 30 countries, pooling clinical trial data and treatment outcomes to create massive datasets that no single institution could generate alone. This collaborative approach has led to faster identification of effective treatments and helped researchers understand how different populations respond to various therapies.
Major cancer centers now participate in real-time data sharing platforms where anonymized patient information flows between continents within hours. The European Organisation for Research and Treatment of Cancer works closely with American and Asian research networks, creating a global brain trust that processes thousands of cases simultaneously. These partnerships have accelerated drug development timelines by years, as researchers can quickly validate findings across diverse populations and genetic backgrounds.
The Uganda Breast Cancer Research Group exemplifies how international collaboration extends beyond wealthy nations, bringing cutting-edge research methodologies to regions previously underserved by clinical trials. Their partnership with European and American institutions has generated crucial data about breast cancer in African populations, revealing genetic variants and treatment responses that might have remained unknown for decades.
Developing Nation Healthcare Access Improvements Expanding Treatment Reach
Healthcare infrastructure improvements in developing nations have created new opportunities for breast cancer research participation and treatment access. Countries like Rwanda, Kenya, and Bangladesh have established cancer treatment centers equipped with modern diagnostic equipment and staffed by internationally trained oncologists. These facilities serve dual purposes: treating local patients while contributing valuable research data to global studies.
Mobile screening programs have revolutionized early detection in rural areas where traditional healthcare infrastructure remains limited. Teams of trained technicians travel with portable mammography equipment, reaching women who previously had no access to breast cancer screening. The data collected from these programs has provided researchers with insights into disease patterns and progression rates in populations that were historically underrepresented in medical literature.
Training programs have created local expertise that reduces dependence on foreign medical teams. Medical schools in countries like Ghana and India now offer specialized oncology programs, often supported by partnerships with established cancer centers in Europe and North America. These programs create sustainable healthcare improvements while building research capacity that contributes to global understanding of breast cancer.
Public-Private Partnership Success Stories Funding Innovation
The Department of Defense Breast Cancer Research Program represents one of the most successful public-private partnerships in medical research, having invested over $4 billion since 1992. This program has funded breakthrough research that led to the development of targeted therapies now used worldwide. The DOD’s unique approach combines military precision with civilian medical expertise, creating an environment where innovative ideas receive rapid funding and development support.
Top pharmaceutical companies breast cancer research initiatives have partnered with government agencies and non-profit organizations to share both costs and risks associated with drug development. Roche’s partnership with the National Cancer Institute has produced multiple FDA-approved treatments, while Pfizer’s collaboration with academic medical centers has advanced personalized medicine approaches that match treatments to individual genetic profiles.
The Breast Cancer Research Foundation has created innovative funding models that attract private donations while maintaining rigorous scientific standards. Their annual gala events raise millions of dollars that support early-stage research projects, many of which later attract additional funding from government sources and pharmaceutical companies. This approach has created a pipeline of promising research that might otherwise lack initial funding.
Patient Advocacy Networks Driving Research Priorities
Patient advocacy groups have transformed from support organizations into powerful forces that shape research priorities and funding decisions. These networks collect patient experiences and treatment outcomes, creating databases that researchers use to identify gaps in current therapies and unmet medical needs. The National Breast Cancer Coalition has successfully lobbied for increased research funding while ensuring that patient perspectives influence study design and outcome measures.
Social media platforms have amplified patient voices, creating global communities where treatment experiences and research opportunities are shared instantly. These digital networks have accelerated patient recruitment for clinical trials and helped researchers identify rare side effects or unexpected treatment benefits that might have gone unnoticed in smaller, traditional study populations.
Patient advocacy networks have also pushed for greater transparency in research funding and results reporting. Their pressure has led to requirements that all clinical trial results be published, regardless of whether they show positive or negative outcomes. This transparency has improved the quality of medical evidence and helped researchers avoid duplicating failed approaches while building on successful strategies.
Prevention and Lifestyle Research Empowering Proactive Health Management
Dietary Studies Revealing Cancer-Fighting Nutritional Strategies
Recent nutritional research has uncovered powerful connections between specific foods and breast cancer prevention. Scientists worldwide are diving deep into how certain nutrients can actively reduce cancer risk, with particularly exciting findings around Mediterranean diet patterns.
The latest studies show that women who consume high amounts of cruciferous vegetables – think broccoli, cauliflower, and Brussels sprouts – have up to 25% lower breast cancer rates. These vegetables contain sulforaphane, a compound that literally switches on protective genes while shutting down cancer-promoting ones.
Omega-3 fatty acids from fish, walnuts, and flaxseeds are getting massive attention from researchers. A major 2024 study tracking 80,000 women over 15 years found that those with the highest omega-3 blood levels had 40% fewer aggressive breast cancers. The anti-inflammatory properties of these healthy fats seem to create a hostile environment for cancer cells.
Green tea consumption has emerged as another game-changer. Breast cancer research shows that women drinking three cups daily have significantly lower cancer recurrence rates. The polyphenols in green tea actually prevent cancer cells from forming new blood vessels they need to grow.
| Food Category | Cancer Risk Reduction | Key Compounds |
|---|---|---|
| Cruciferous Vegetables | 25% | Sulforaphane |
| Omega-3 Rich Foods | 40% | EPA/DHA |
| Green Tea | 30% | Polyphenols |
| Berries | 20% | Anthocyanins |
Exercise Research Demonstrating Risk Reduction Benefits
Physical activity research has produced some of the most convincing evidence for breast cancer prevention. The data is clear: moving your body regularly creates a protective shield against cancer development.
Large-scale studies reveal that women who exercise regularly slash their breast cancer risk by 20-40%. The sweet spot appears to be 150 minutes of moderate exercise weekly – that’s just 30 minutes, five days a week. High-intensity interval training shows even more dramatic results, with some studies reporting up to 50% risk reduction.
Exercise works its magic through multiple pathways. Physical activity reduces estrogen levels, particularly important since many breast cancers are hormone-driven. Regular workouts also boost immune system function, helping your body identify and destroy abnormal cells before they become problematic.
The timing matters too. Research from the Department of Defense breast cancer research program shows that exercise during adolescence and young adulthood provides lifelong protection. Women who were active in their teens and twenties maintain lower cancer risks even decades later.
Post-diagnosis, exercise becomes even more critical. Cancer survivors who maintain active lifestyles have 50% lower recurrence rates and significantly better survival outcomes. The research is so strong that many oncologists now prescribe exercise as part of standard treatment protocols.
Environmental Factor Investigations Identifying Preventable Causes
Environmental breast cancer research has exploded in recent years, revealing surprising connections between everyday exposures and cancer development. Scientists are mapping out exactly which chemicals and environmental factors we can control to protect ourselves.
Endocrine-disrupting chemicals top the list of concerns. These hormone-mimicking substances hide in plastics, cosmetics, and household cleaners. Recent studies show women with highest exposure levels have double the breast cancer risk compared to those with minimal exposure. The good news? Simple swaps like glass containers instead of plastic and natural cleaning products can dramatically reduce exposure.
Air pollution research has uncovered alarming links to breast cancer. Women living near major highways or in high-pollution areas show 30% higher cancer rates. Fine particulate matter appears to trigger inflammatory processes that can kickstart cancer development. This research has sparked global initiatives to improve air quality standards.
Night shift work and artificial light exposure represent emerging risk factors. Women working rotating shifts for more than 15 years have 50% higher breast cancer rates. The disruption of natural circadian rhythms suppresses melatonin production, a hormone with powerful anti-cancer properties.
The breast cancer research foundation and similar organizations are now funding large-scale studies to identify which environmental factors pose the greatest risks. These investigations are revealing that many exposures are completely preventable through informed choices about where we live, work, and what products we use daily.
The landscape of breast cancer research has never been more promising. From groundbreaking treatments that are transforming patient outcomes to revolutionary diagnostic tools that catch cancer in its earliest stages, scientists and medical professionals are making remarkable strides. Clinical trials continue to offer hope for future treatments, while global research initiatives are speeding up medical progress across borders. At the same time, prevention and lifestyle research is giving people more power to take control of their health before cancer even develops.
These advances represent more than just scientific progress – they’re changing real lives every day. If you or someone you know is facing breast cancer, stay connected with your healthcare team about these emerging options. Keep up with the latest research, ask about clinical trial opportunities, and remember that early detection saves lives. The future of breast cancer treatment looks brighter than ever, and staying informed about these developments could make all the difference in your health journey.
FAQs
What are the most recent breakthroughs in breast cancer research?
Recent breakthroughs include new targeted therapies that work better for specific types of breast cancer, improved immunotherapy treatments that help the body’s immune system fight cancer cells, and advances in personalized medicine based on genetic testing. Researchers have also developed better ways to detect cancer early and new surgical techniques that preserve more healthy tissue.
How do I find out about current breast cancer clinical trials?
You can search for clinical trials through ClinicalTrials.gov, which is run by the National Institutes of Health. Your doctor can also help you find trials that might be right for you. Many cancer centers and hospitals also have clinical trial coordinators who can provide information about studies happening in your area.
What new treatments are being tested in clinical trials right now?
Current trials are testing new drug combinations, CAR-T cell therapy (where immune cells are modified to fight cancer), new hormone therapy options, and treatments that target cancer stem cells. Some trials are also looking at ways to prevent breast cancer in high-risk women and testing new radiation therapy techniques.
Are there global programs working on breast cancer research?
Yes, there are many international efforts. The World Health Organization has global cancer initiatives, and organizations like Breast Cancer Research Foundation fund studies worldwide. Many countries also work together through programs like the International Breast Cancer Study Group to share research findings and coordinate large studies.
How long does it take for new breast cancer treatments to become available to patients?
It typically takes 10-15 years for a new treatment to go from early research to being approved for general use. However, patients may be able to access promising treatments earlier through clinical trials. Some treatments may get fast-track approval if they show exceptional results for serious conditions.
What is precision medicine and how does it help breast cancer patients?
Precision medicine means choosing treatments based on the specific characteristics of your cancer and your genetic makeup. Doctors test tumor samples to see which genes are changed and then pick treatments that work best for that specific type of cancer. This approach often leads to better results and fewer side effects.
Are there any new ways to prevent breast cancer being researched?
Researchers are studying several prevention approaches, including medications that might reduce cancer risk in high-risk women, lifestyle changes that could lower risk, and vaccines that might prevent certain types of breast cancer. Some studies are also looking at whether certain supplements or dietary changes might help.
How do researchers decide which patients should participate in clinical trials?
Each clinical trial has specific requirements called eligibility criteria. These might include the type and stage of cancer, previous treatments received, age, and overall health status. The goal is to test treatments safely and get reliable results. Your medical team can help determine if you meet the criteria for specific trials.
What role does artificial intelligence play in current breast cancer research?
AI is being used to analyze medical images more accurately, predict which treatments will work best for individual patients, and speed up drug discovery. It also helps researchers analyze large amounts of data to find patterns that might lead to new treatments or better ways to diagnose cancer early.
How can I stay updated on the latest breast cancer research developments?
You can follow reputable medical websites, sign up for newsletters from cancer organizations like the American Cancer Society, and talk to your healthcare team about new developments. Medical journals often publish research updates, and many cancer centers share news about their latest studies on their websites.
